Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.

Eur J CancerSep 11, 2026 (epub)
Clinical ResearchOncology (Medical)

Tshilidzi M Klingler, Uwe M Martens, Jorge Riera-Knorrenschild et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase II randomized controlled trial evaluated health-related quality of life (HRQoL) in 105 patients with RAS wild-type metastatic colorectal cancer receiving mFOLFOXIRI + panitumumab versus FOLFOXIRI. The study found no statistically significant differences in overall HRQoL or specific dimensions between the treatment arms at baseline and after 12 weeks.

Key findings

  • No statistically significant differences in overall HRQoL between mFOLFOXIRI + panitumumab and FOLFOXIRI at 12 weeks.
  • Patients on mFOLFOXIRI + panitumumab had numerically worsened pain scores during treatment.
  • Improved social functioning was observed in patients receiving mFOLFOXIRI + panitumumab.

Why it matters

Understanding the impact of treatment on HRQoL is crucial for clinicians when considering therapy options for patients with metastatic colorectal cancer, as it informs the balance between treatment efficacy and quality of life.

Source

PubMed · PMID 42743885

Published in Eur J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.